Rachel E. Sanborn, MD
Dr. Rachel E. Sanborn is a medical oncologist at the Providence Cancer Institute and co-director of the Providence Thoracic Oncology Program in Portland, Oregon. She treats patients with lung cancers and thoracic malignancies, including malignant pleural mesothelioma. She enjoys the close bond that she forms with her patients and their families, despite the difficult process that they are working through. She believes that it is her job to provide patients with as much information as possible so they can make their decisions with confidence, stressing the importance of keeping an open and honest line of communication.[1]
Education and Career
Dr. Sanborn completed her undergraduate education at Cornell University, where she earned a Bachelor of Arts degree in Biology. She earned her medical degree at the Oregon Health and Science University School of Medicine, then completed an internship and residency in Internal Medicine at the University of Illinois College of Medicine in Chicago. She returned to Oregon Health & Science University to complete a fellowship in Hematology and Oncology.[1]
Professional Memberships and Activities
Dr. Sanborn is a member of several professional organizations and societies, including:[1]
- American Society of Clinical Oncology
- Society for Immunotherapy of Cancer
- International Association for the Study of Lung Cancer
- Lung Cancer Research Foundation
- Co-chair of the Hoosier Cancer Research Network Thoracic Clinical Trial Working Group
She is also an Institutional Review Board Member for Providence Health and Services.
Research
In her role as Medical Director of the Phase 1 Clinical Trials Program at the Earle A. Chiles Research Institute at Providence Cancer Institute, Dr. Sanborn is responsible for one of the most robust portfolios of early-phase cancer clinical trials on the West Coast. She is personally involved in clinical trials and studies of immunotherapy drugs, targeted therapies, and combination therapies for patients with thoracic malignancies.[1]
Recently active clinical trials she has been involved with include:[footnote num=”2″}
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer. Start of enrollment: 2008 Jan 01. COMPLETED. PHASE 2
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer. Start of enrollment: 2010 Oct 14. COMPLETED. PHASE 1
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. Start of enrollment: 2011 Jul 01. ACTIVE, NOT RECRUITING. PHASE 2
Dr. Sanborn’s recent publications and presentations include:[footnote num=”2″}
Publications:
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial. Byoung Chul Cho, Dong-Wan Kim, Alexander I Spira, Jorge E Gomez, Eric B Haura, Sang-We Kim, Rachel E Sanborn, Eun Kyung Cho, Ki Hyeong Lee, Anna Minchom, Jong-Seok Lee…>; Nature Medicine. 2023 Oct 1
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Keunchil Park, Joshua K Sabari, Eric B Haura, Catherine A Shu, Alexander Spira, Ravi Salgia, Karen L Reckamp, Rachel E Sanborn, Ramaswamy Govindan, Joshua M Bauml, Jos…>; Lung Cancer. 2023 Apr 1
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/…Paolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, James Larkin, Georgina V Long, Rachel E Sanborn, Vanna Chiarion-Sileni, Brigitte Dréno, Stéphane Dalle, Dirk Sc…> ;Journal of Clinical Oncology. 2023 May 20
Lectures:
Targeted Oncology Cased-Based Peer Perspectives on Targeted Therapy and IO for Lung Cancer Tacoma, WA (Virtual Meeting) – 8/2020
Case-Based Peer Perspectives in EGFR-Mutated NSCLC and in Small Cell Lung Cancer, Tacoma, WA (Virtual Meeting) – 6/2020
Maximizing the Benefits of Targeted Therapies, Chicago, IL (ASCO Virtual Meeting) – 5/2020
